Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FinlandBack to Finland

Clinical trials in Helsinki – page 3

400 clinical trials in Helsinki, Finland across 6 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

FinlandOur site in FinlandKliinisetTutkimukset.fi(opens in a new tab)
Helsinki at a glance
400
clinical trials
  • Research sites6
Type of trial
Recruitment status
Quick filters

400 trials in Helsinki

Open in trial search

Non-Hodgkin's lymphoma

Recruiting

Phase 1/2 Study Evaluating Safety and Activity of GSK5926371 in Adults with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Sponsor:Glaxosmithkline Research & Development Limited

Pneumococcal immunisation

Recruiting

Safety of PF-07872412 versus 20‑valent pneumococcal conjugate vaccine in healthy infants for prevention of pneumococcal disease

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:PF-07831695
  • Sponsor:Pfizer Inc.

Systemic scleroderma

Recruiting

A double‑blind, placebo‑controlled trial of oral BI 1015550 in patients with systemic sclerosis

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Interstitial lung disease

Recruiting

Safety, Pharmacokinetics, and Exploratory Efficacy of BI 1015550 and Nerandomilast in Children and Adolescents Aged 2‑17 Years With Fibrosing Interstitial Lung Disease

Investigational
Countries:FinlandFinland
  • Participants:0–17 years
  • Substances:BI 1015550
  • Sponsor:Boehringer Ingelheim Espana S.A.

Pancreatic carcinoma metastatic

Recruiting

Randomized Study of INCB161734 Plus Standard Chemotherapy Drug Combination in Untreated KRAS G12D Metastatic Pancreatic Ductal Adenocarcinoma Patients

Registered drug
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Incyte Corp.

Plasma cell myeloma refractory

Recruiting

Phase II Study of Teclistamab Plus Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma After 1–3 Prior Therapies

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pomalidomide
  • Sponsor:Odense University Hospital

Acute myeloid leukaemia

Recruiting

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study of ODM-212 in Combination with Cancer Treatment for Patients with Advanced Solid Tumours

Recruiting
Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Orion Corporation

Systemic lupus erythematosus

Recruiting

Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus

Investigational
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Neoplasm

Recruiting

EIK1005 Alone and with Pembrolizumab for Advanced Solid Tumors in Patients with MSI-H or dMMR Tumors

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Eikon Therapeutics Inc.

Neuroendocrine carcinoma

Recruiting

Obrixtamig, Carboplatin, and Etoposide for First-Line Treatment of Advanced Extrapulmonary Neuroendocrine Carcinoma in DLL3-Positive Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Boehringer Ingelheim Espana S.A.

Other cities in Finland

The busiest research cities in the country

All 28 cities in Finland

Clinical research in Helsinki

What the registry says about research in the country

01 Infectious Disease Prevention

Clinical trials focusing on vaccine development against various infectious diseases, including studies of RSV, meningococcal, and influenza vaccines in different age groups.

  • Respiratory Virus Vaccines
  • Bacterial Disease Prevention
  • Immune Response Studies

Research emphasizes safety, immunogenicity, and efficacy in diverse populations from infants to older adults.

02 Neurological Conditions

Innovative research in stroke treatment and cerebral vasculature disorders, including studies on acute ischemic stroke interventions and vasoconstriction syndrome management.

  • Stroke Therapeutics
  • Dementia Prevention
  • Vascular Disorders

Trials combine therapeutic interventions with lifestyle modifications to improve patient outcomes.

03 Metabolic Disorders

Studies addressing obesity management through novel therapeutic approaches combined with lifestyle interventions, focusing on weight-related complications.

  • Weight Management
  • Metabolic Health
  • Lifestyle Interventions

Research emphasizes comprehensive treatment strategies for metabolic health improvement.

04 Oncology Research

Advanced studies in acute myeloid leukemia treatment, investigating combination therapies for patients unsuitable for intensive chemotherapy.

  • Blood Cancer Treatments
  • Targeted Therapies
  • Novel Drug Combinations

Focusing on personalized treatment approaches for specific genetic mutations.

Back to FinlandAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.